Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 11/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 11/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121736 | 0.88 | HSD11B1 (0.40) | BCL9CTNNB1HSD11B1 | |
| SCHEMBL23120510 | 0.88 | BCL9 (0.40) | BCL9CTNNB1HSD11B1MGLLTSHR | |
| Hydrochloric Acid SCHEMBL23123755 | 0.87 | BCL9 (0.41) | BCL9CTNNB1HSD11B1MGLLTSHR | |
| SCHEMBL23121719 | 0.85 | HSD11B1 (0.38) | BCL9CTNNB1HSD11B1AURKB | |
| Hydrochloric Acid SCHEMBL23121759 | 0.84 | BCL9 (0.38) | BCL9CTNNB1HSD11B1AURKB | |
| SCHEMBL23122009 | 0.81 | HSD11B1 (0.37) | BCL9CTNNB1HSD11B1MGLLTSHR | |
| SCHEMBL30008961 | 0.81 | HSD11B1 (0.37) | BCL9CTNNB1HSD11B1MGLLTSHR | |
| SCHEMBL27152443 | 0.78 | TSHR (0.38) | MGLLTSHR | |
| Trifluoroacetic Acid SCHEMBL30009822 | 0.78 | HSD11B1 (0.35) | BCL9CTNNB1HSD11B1MGLLTSHR | |
| SCHEMBL27137559 | 0.77 | BCL9 (0.36) | BCL9CTNNB1MGLLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | BCL9 25/4885CTNNB1 2136/4885HSD11B1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.